HomeInsightsStock Comparison

Ind Swift Laboratories Ltd vs Natco Pharma Ltd Stock Comparison

Ind Swift Laboratories Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: Jun 06, 2025

Key Highlights

  • The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 92.7 as of 06 Jun 15:33.
  • The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 1.4 on March 2024 . This represents a CAGR of -54.96% over 2 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 years.
  • The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 128.22 crore on March 2020 to ₹ 580.82 crore on March 2024 . This represents a CAGR of 35.27% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 years.
  • The revenue of Ind-Swift Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 22.48 crore. This represent the decline of -100% The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71%.
  • The ebitda of Ind-Swift Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ -0.72 crore. This represent the decline of -100% The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63%.
  • The net profit of Ind-Swift Laboratories Ltd changed from ₹ 17.4 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% .
  • The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ind-Swift Laboratories Ltd

  • Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, India.
  • The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
  • Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
  • Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
  • Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Ind-Swift Laboratories Ltd News Hub

News

Ind-Swift Laboratories schedules board meeting

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 30 ...

Read more

24 May 2025 18:25

News

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was sched...

Read more

14 Feb 2025 11:01

News

Ind-Swift Laboratories announces cessation of director

Ind-Swift Laboratories announced the cessation of Dr. Ashwani Kumar Vig as Independent Dir...

Read more

13 Feb 2025 19:26

News

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was sched...

Read more

13 Feb 2025 11:33

News

Ind-Swift Laboratories to announce Quarterly Result

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 12 ...

Read more

07 Feb 2025 16:48

News

Ind-Swift Laboratories to hold EGM

Ind-Swift Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Compa...

Read more

21 Jan 2025 14:05

Natco Pharma Ltd News Hub

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

News

Natco Pharma update on launch of Risdiplam in India

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Comp...

Read more

08 Apr 2025 11:16

News

Natco Pharma Ltd up for fifth session

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 8...

Read more

07 Mar 2025 13:00

News

Natco Pharma Ltd soars 1.69%

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837...

Read more

25 Feb 2025 13:05

News

Natco Pharma slips as Q3 PAT slides 38% YoY to Rs 132 cr

Profit before tax in Q3 FY25 stood at Rs 163.7 crore, down 36.13% as against Rs 256.3 cror...

Read more

13 Feb 2025 11:11

SWOT Analysis Of Ind-Swift Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Ind-Swift Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ind-Swift Laboratories Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Natco Pharma Ltd?

Market cap of Ind-Swift Laboratories Ltd is 588 Cr while Market cap of Natco Pharma Ltd is 15,432 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Natco Pharma Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Natco Pharma Ltd?

As of June 6, 2025, the Ind-Swift Laboratories Ltd stock price is INR ₹97.06. On the other hand, Natco Pharma Ltd stock price is INR ₹861.6.

How do dividend payouts of Ind-Swift Laboratories Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions